Fresenius Medical Care achieves revised 2018 targets and accelerates investments for future growth
· Growth trend unchanged: organic revenue growth of 4% for full year 2018
· Net income growth of 60% (14% on a comparable basis) at constant currency
· 22nd consecutive dividend increase proposed: +10% to EUR 1.17
· Share buyback program of up to EUR 1bn over the next 2 years
· Meaningful investments in 2019 to capture future growth opportunities and optimize cost base
· Significantly accelerated net income growth in 2020 expected.